CASP1 and hematocrit: Administering these inhibitors for eight weeks exhibited beneficial effects through reduction of thyroid volume, lymphocyte infiltration, serum TGAb, TPOAb and TSH levels, and attenuation of Caspase-1, IL-1β expression without impacting the expression of USP1 or inflammasomes upstream of pyroptosis (Fig. 5B–I), signifying the importance of TFCs' pyroptosis in HT development.